急性胰腺炎5种药物治疗方案的成本-效果分析

592ChinaPharmacy2005Vol.16No.82005168::,,-,5--,--,5-1*,2(11,421900;21,421900)R956C1001-0408(2005)08-0592-03:5-:-,(A)(B)(C)(D)(E):526781243071168110117010891041098104;96188%93155%92186%92100%96155%;E-,11153;D1,ABCE3241331321176141071196:E;;-*::0734-5675084E-mail:zhouwurang@yahoo1com1cn,(AP)[1],5-,AP1111,1998412004531CT()[2],:(1);(2)3,H2;(3);(4)5,1641121645,11Tab1CasegroupingA()0.1mg/120ml,15%250ml,23/,4B()10IU/15%500ml,23/,5C250mg/25%500ml,1/,6D()10mg/1,1/6,5E50ml50ml(50g),1/14,5Cost-effectivenessAnalysison5DrugTreatmentSchemesintheTreatmentofAcutePancreatitisZHOUWeiran(TheThirdAffiliatedHospitalofNanhuaUniversity,Hengyang421900,China)ZHENGDexiang(TheCadres’SanatoriumofHengyang,Hengyang421900,China)ABSTRACTOBJECTIVE:Toevaluatethecost-effectivenessof5kindsofdrugtreatmentregimesinthetreatmentofac-utepancreatitis1METHODS:Thecost-effectivenessmethodinpharmacoeconomicswasadoptedintheretrospectiveanalysisofthefollowing5treatmentschemes:octreotideingroupA,ulinastatiningroupB,fluorouracilingroupC,nifedipineingroupDandrheidecoctioningroupE1RESULTS:Thecostsforthe5treatmentschemeswere2678124,3071168,1101170,1089104,and1098104yuanrespectively;Theeffectiveratesofthe5schemeswere96188%,93155%,92186%,92100%and96155%respectively;ThecosteffectivenessratioofschemesEwastheminimum,whichwas11153yuan;OnthebasisofgroupD,thesuperadditioncostsforgainingoneeffectivenessunitforschemeA,B,CandEwere324133,1321176,14107,1196yuanrespectively1CONCLUSIONS:Amongthe5schemes,schemeEwasthebestone1KEYWORDSAcutepancreatitis;Pharmacoeconomics;Cost-effectivenessanalysis2005168ChinaPharmacy2005Vol.16No.85932Tab2Characteristicsofageandgenderofeachgroup(n)(xs,)(n)A3238.217.11517B3137.418.21516C2836.516.81315D2537.317.31213E2939.118.114153Tab3Comparisonoftherapeuticeffectsamonggroups(n)(n)(n)(%)(%)A3229290.6396.88B3126383.8793.55C2824285.7192.86D2520380.0092.00E2925386.2196.555-Tab5Analysisofcost-effectivenessofeachgroup(C,)(E1,%)(E2,%)C/E1C/E1C/E2C/E2A2678.2490.6396.8829.55149.5027.41324.33B3071.6883.8793.5536.62512.3132.851321.76C1101.7085.7192.8612.462.2211.4914.07D1089.0480.0092.0013.61-11.84-E1098.0486.2196.5511.531.4510.291.966Tab6Analysisofsensitivity(C,)(E1,%)(E2,%)C/E1C/E1C/E2C/E2A2359.2090.6396.8826.03114.9424.35249.35B2803.5483.8793.5533.43430.5329.981110.76C1147.2085.7192.8613.381.7212.3510.89D1137.4080.0092.0014.22-12.36-E1140.8186.2196.5513.240.5511.810.74AP,2211,,P0105;X2,P0105,,2212AP2,,3:,(500IU);:,,;:,,213,,[3],533,ABCE(P0105),D(P01001);EA(P0105),BCD(P0105)214-21411(C):APAP2(C)=++[4]=+=(C)+(C)+(C)+(C)+(C)+(C),C=;,;C,18/;AP13/;AP2,2/;1,1315/;3/,5/,,2,,(C)=(C)+(C)+(),,,35/,C=C+C+C+C+C+C+C544Tab4Comparisonofcostsofamongtheschemes(n)(xs,)A322676.24256.85B313071.68286.20C281101.70458.50D251089.04621.51E291098.04301.20:(P0105)Note:significantdifferenceswerefoundingroupcomparison(P0105)21412-:-(C)(E)(C/E)1[5],--,,1,-(C/E),1,[6]D-,55,E-,D1%E,E21413:,[7][8],,,,,,(,),,C15%,C,CCCCC10%,,6594ChinaPharmacy2005Vol.16No.82005168-*,,(,100853)R956C1001-0408(2005)08-0594-03::56,,A(18,,80mg)B(21,,600mg)C(17,,1000mg),,-:ABC(C)99010013391101886170;(E)5156%14129%35129%;(C/E)1781069317153146;A,BC(C/E)3919930116:CAB,,C;;;;-*,::010-66937710E-mail:weimduan@sina1comCost-effectivenessAnalysisonDifferentDosesofMethylprednisoloneTreatmentRegimesonPostopera2tiveTraumaticReactioninPatietentsofCervicalSpondyloticMyelopathyWEIMin,LiuZhengsheng,TAOSheng(Dept1ofOrthopaedics,GeneralHospitalofPLA,Beijing100853,China)ABSTRACTOBJECTIVE:Toevaluatetheeconomiceffectsofdifferentdosesofmethylprednisolonetreatmentregimesontraumaticreactioninpatientswithcervicalspondyloticmyelopathyafteranteriordecompressiveoperation1METHODS:56cervicalspondyloticmyelopathycaseswhohavebeensubjectedtoanteriordecompressiveoperationwerechosentobethesub2jects1The56casesweredividedinto3groupsandtreatedwithdifferentdosageofmethylprednisolone,theinitialdoseforgroupA(18cases,lowdosegroup)was80mg;theinitialdoseforgroupB(21cases,mediumdosegroup)was600mgandthatforgroupC(17cases,largedosegroup)was1000mg,theimprovementofclinicalsymptomofeachgroupwasobservedre2spectivelyandthecost-effectivenessesofthethreegroupswerecompared1RESULTS:ThecostsoftheA,B,Cgroupswere990100,1339110and1886170yuanrespectively;theeffectivenessrates(E)oftheA,B,Cgroupswere5156%,14129%and35129%respectively;Thecostsforeachunitofobviouseffectiveness(C/E)oftheA,B,Cgroupswere178106,93171and53146yuanrespectively;OnthebasisofgroupA,theneededcostsofgroupBandCwere39199and30116yuanrespectivelyforeachobviouseffectivenessunitincrease(C/E)1CONCLUSION:ComparedwithgroupAandB,theeffectivenessratesofgroupChadabiggerincreasewhiletheneededcostforeachunitofobviouseffectivenesswasthelowest,therefore,thedoseregimenofgroupCismorerational1KEYWORDSCervicalspondyloticmyelopathy;Postoperativetraumaticreaction;Methylprednisolone;Pharmacoeco2nomics;Cost-effectivenessanalysis3345,A,,D,,E-;,ABCED1(/),(:)149150/324133512131/13211762122/141071145/1196,E-6,--,,EAP,,,,A,,(),A[1]1[J]1,2004,24(3):1291[2]1()[J]1,2004,24(3):1901[3],13-[J]1,2001,12(8):4701[4],1[J]1,1995,4(1)